In a 50-patient trial conducted by Hofman et al using LuPSMA alone against mCRPC, median OS was 13.3 months.
Median OS in the 56-patient LuPIN trial using LuPSMA + NOX66 was 19.7 months.
There was one significant difference: the LuPIN patients were MORE resistant to treatment, having had to have failed more prior therapies.
The LuPIN result was indeed remarkable.
Ann: LuPIN Survival Outcome Confirmed by Conference Presentation, page-10
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
